CMG is now offering Semaglutide injections for weight loss!
Our weight loss program offers Semaglutide injections, starting with once-a-week injections for seven weeks. If you desire to continue the therapy, another visit must be made after completing your seven weeks. You can also add a Skinny Shot package to your weight loss regimen to increase your benefits.
Approximately 70% of American adults are obese or overweight. Obesity, or being overweight, is a severe health issue associated with leading causes of death, including heart disease, stroke, and diabetes. It is linked to an increased risk of certain types of cancer. Losing 5% to 10% of body weight through diet and exercise has been associated with a reduced risk of cardiovascular disease in adult patients with obesity or overweight.
Semaglutide, or Wegovy, works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that targets areas of the brain that regulate appetite and food intake. The medication dose must be increased gradually over 16 to 20 weeks to 2.4 mg once weekly to reduce gastrointestinal side effects.
Semaglutide should not be used with other semaglutide-containing products, other GLP-1 receptor agonists, or other products intended for weight loss, including prescription, over-the-counter, or herbal products. Semaglutide has not been studied in patients with a history of pancreatitis.
Semaglutide's safety and efficacy were studied in four 68-week trials. Three were randomized, double-blind, placebo-controlled trials (including 16 weeks of dose increases), and one was a double-blind, placebo-controlled, randomized withdrawal trial in which patients receiving Wegovy either continued with the treatment or switched to a placebo. More than 2,600 patients received Wegovy for up to 68 weeks in these four studies, and more than 1,500 patients received a placebo.
The largest placebo-controlled trial enrolled adults without diabetes. The average age at the start of the problem was 46 years, and 74% of patients were female. The average body weight was 231 pounds (105 kg), and the average BMI was 38 kg/m2. Individuals who received Wegovy lost an average of 12.4% of their initial body weight compared to individuals who received a placebo. Another trial enrolled adults with type 2 diabetes. The average age was 55 years, and 51% were female. The average body weight was 220 pounds (100 kg), and the average BMI was 36 kg/m2. In this trial, individuals who received Wegovy lost 6.2% of their initial body weight compared to those who received a placebo.
The most common side effects include nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar) in patients with type 2 diabetes, flatulence (gas buildup), gastroenteritis (an intestinal infection) and gastroesophageal reflux disease (a type of digestive disorder).
The prescribing information for Semaglutide contains a boxed warning to inform healthcare professionals and patients about the potential risk of thyroid C-cell tumors. Semaglutide should not be used in patients with a personal or family history of medullary thyroid carcinoma or with a rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
